Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 3/20 | 0.32 |
| ▸ | CA1 | P00915 | 2/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL304559 | 0.86 | MC4R (0.35) | ALDH1A1MEN1KMT2ALMNACA1 | |
| SCHEMBL25570266 | 0.84 | CA12 (0.40) | ALDH1A1TP53HPGDTSHRMEN1 | |
| SCHEMBL20780287 | 0.84 | CA12 (0.43) | ALDH1A1TP53HPGDTSHRMEN1 | |
| SCHEMBL8909949 | 0.83 | KMT2A (0.45) | ALDH1A1TP53HPGDTSHRMEN1 | |
| SCHEMBL27381735 | 0.83 | TSHR (0.32) | ALDH1A1TSHRHDAC1HDAC6CA1 | |
| SCHEMBL304558 | 0.81 | MEN1 (0.33) | ALDH1A1MEN1KMT2ALMNACA1 | |
| SCHEMBL18600473 | 0.81 | CA12 (0.50) | ALDH1A1TP53HPGDTSHRLMNA | |
| SCHEMBL7603535 | 0.81 | ALDH1A1 (0.34) | ALDH1A1TP53TSHRMEN1KMT2A | |
| SCHEMBL13301217 | 0.79 | TSHR (0.37) | ALDH1A1TSHRMEN1KMT2ACA1 | |
| SCHEMBL16125928 | 0.78 | CA14 (0.39) | ALDH1A1MEN1KMT2AHDAC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230167105-A1 | BCL-2 PROTEIN INHIBITORS | RECURIUM IP HOLDINGS, LLC | 2023-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230167105-A1 | BCL-2 PROTEIN INHIBITORS | BCL2, BCL2L1, BCL2L2 | ALDH1A1 2821/4885TP53 23/4885HPGD 2009/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.